Work

NTLA5001, a T Cell Product Candidate with CRISPR-Based Targeted Insertion of a High-Avidity, Natural, WT1-Specific TCR, Shows Efficacy in In Vivo Models of AML and ALL

Year: 2020

Type: article

Source: Blood

DOI: 10.1182/blood-2020-143119

Authors: Eliana Ruggiero, Dai Liu, Aaron Prodeus, Amy M Becker, Maxwell Foisey, Ishina Balwani, Ivy Dutta, Qingzhan Zhang, Simo M Arredouani, Mark McKee, Fabio Ciceri, Laura Sepp-Lorenzino, Chiara Bonini, Birgit C Schultes

Institutions: IRCCS Ospedale San Raffaele, Intellia Therapeutics (United States), Vita-Salute San Raffaele University

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3095459615

FWCI: 0.091

Cites:

Cited by: 1

Related to: 10